Sanofi has choosen EUROAPI as the name for the future European company dedicated to the development, production and marketing of active pharmaceutical ingredients (APIs).   EUROAPI will represent the “made in Europe” API state-of-the-art industrial capabilities and technologies, with approximately €1 billion in expected sales by 2022. It will rank number 1 in small molecules API, and number 2 on the global API market, according to the company. Addressing recent increasing medicine shortages, EUR...